Spark Therapeutics
Roche set to acquire Spark Therapeutics in $4.8 billion deal
February 25, 2019Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma
Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …
Strong efficacy but serious side-effects with Spark’s haemophilia drug drop shares by 30%
August 8, 2018Research and Development Spark Therapeutics, haemophilia, pharma
Spark Therapeutics has been left reeling after it revealed new data on its haemophilia A treatment, which, while promising in …
Spark hands over Luxturna rights outside US to Novartis for $170m
January 25, 2018Sales and Marketing Luxturna, Novartis, Spark Therapeutics, pharma
Novartis has confirmed a deal worth a potential $170 million with Spark Therapeutics to develop and commercialise its gene therapy …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
Spark’s bright idea on $850,000 blindness gene therapy
January 3, 2018Sales and Marketing : Pharma, Spark Therapeutics, biotech, drugs, pharma, pharmaceutical
Spark Therapeutics knew that it had to think very carefully about where it pitched its price for its inarguably ground-breaking …
Spark gains approval for gene therapy, paving way for first $1m treatment
December 20, 2017Research and Development, Sales and Marketing Spark Therapeutics, biotech, drugs, gene therapy, pharma, pharmaceutical
The FDA handed approval to Spark Therapeutics’ gene therapy for an inherited eye disorder, making it the first treatment of …
Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug
July 22, 2016Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001
Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
Spark Therapeutics buys Genable Tech for $6 million in cash and stock deal
March 11, 2016Business Services, Medical Communications Genable Technologies, Spark Therapeutics, cash & stock, genetic technologies, merger & acquisitions
Spark Therapeutics (Nasdaq: ONCE) said it has acquired Ireland-based Genable Technologies, a privately-held gene therapy firm for $6 million in a cash …
